SCHEDULE: Timothy G. Youngquist Trust Discloses Coherus Oncology Stake

The Timothy G. Youngquist 2020 Irrevocable Trust has reported beneficial ownership of 8.267% of Coherus Oncology, Inc. common stock.

Summary

• The Timothy G. Youngquist 2020 Irrevocable Trust, managed by Trista Kragh as trustee, has filed a Schedule 13G, indicating a significant ownership stake in Coherus Oncology, Inc.
• The trust beneficially owns 12,790,800 shares of Coherus Oncology's common stock, representing 8.267% of the outstanding shares.
• This ownership percentage is calculated based on 154,217,609 shares outstanding as of April 16, 2026, as per Coherus Oncology's Definitive Proxy Statement filed on April 20, 2026.
• The trust also holds call options for 500,000 shares of common stock, which are considered in the calculation of beneficial ownership as they grant the right to acquire shares within 60 days.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it is a routine disclosure of beneficial ownership and does not provide new operational or financial performance information about the company itself.

Positives

• The Timothy G. Youngquist 2020 Irrevocable Trust has established a substantial beneficial ownership stake of 8.267% in Coherus Oncology, Inc.
• The trust's holdings include direct ownership of 12,790,800 shares and an additional 500,000 shares underlying call options, demonstrating a strong conviction in the company.

Risks

• The filing does not explicitly detail any risks associated with the investment or the company's operations.

Future Outlook

The filing does not contain any forward-looking statements or guidance from the company. It solely reports on the ownership stake of the Timothy G. Youngquist 2020 Irrevocable Trust.

Industry Context

StockSavvy.ai notes that significant ownership filings like this Schedule 13G can signal increased institutional interest or a strategic shift in a company's shareholder base, potentially impacting market perception and stock performance.

Stakeholder Impact

• Shareholders may view the increased stake by the Timothy G. Youngquist 2020 Irrevocable Trust as a positive signal of confidence in the company's future, potentially influencing share price.
• The trust's significant ownership could lead to increased engagement with company management regarding strategic decisions.

Key Dates

Keywords

Coherus Oncology, Schedule 13G, Timothy G. Youngquist 2020 Irrevocable Trust, Beneficial Ownership, Common Stock, Call Options, SEC Filing, Institutional Investor